The Biotech Startups Podcast

In this episode of The Biotech Startups Podcast, host Jon Chee continues his conversation with Fengru Lin, CEO and co-founder of TurtleTree. Fengru shares how rigorous sales training at Salesforce and entrepreneurial autonomy at Google Cloud shaped her approach to customers, investors, and organizational change—then traces how a cheese-making hobby, poor dairy supply chains, and exposure to cell-based meat and seafood startups led to TurtleTree’s founding, early patents, and strategic pivot toward precision fermentation of high-value milk proteins.

In this episode of The Biotech Startups Podcast, Jon Chee sits down with Fengru Lin, CEO and co-founder of TurtleTree, a biotech company using precision fermentation to produce LF+, the world’s first sustainably made lactoferrin, and ultimately reimagine how food is produced. Drawing on a nontraditional path into biotech—from Girl Guides in Singapore to sales roles in transactional security and global regulatory environments—Fengru shares how an early love of planning, operations, and people has shaped her approach to leadership and company building.

In this final episode of The Biotech Startups Podcast series, Jon Chee sits down with Mati Gill, CEO of AION Labs, to unpack where AI value is actually being created in biopharma—and what comes next. Mati lays out three pillars driving a post-hype phase of sustainable growth, explains why the industry is structurally conservative for good reasons, and shares how AION Labs is already preparing for the quantum computing wave before it arrives.

Jon Chee sits down with Mati Gill, CEO of AION Labs — an Israeli venture studio backed by AstraZeneca, Merck, Pfizer, Teva, AWS, and the Israel Biotech Fund. Mati breaks down how AION Labs builds AI-native pharma companies from the ground up: industry-grade problem statements, multidisciplinary teams, and pharma partner POC commitments locked in before a startup is formed.

In this episode of The Biotech Startups Podcast, Jon Chee sits down with Mati Gill, CEO of AION Labs. Mati traces his path from juggling a minister's bureau with Israeli law school to joining Teva as an intern with no private-sector experience, then learning a 45,000-person org from the chart up — until Teva's financial crisis handed him the mandate to build the innovation program that became AION Labs.